Levodopa Fatty Acid Derivatives for Sustained Dopamine Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current levodopa treatments for Parkinson's disease result in marked plasma drug concentration fluctuations, leading to inconsistent dopamine levels in the brain due to its short plasma half-life and rapid degradation, which causes motor fluctuations and dyskinesia.
Innovation Solution
Development of levodopa derivatives with fatty acid or fatty alcohol substituents that protect levodopa from premature degradation, allowing for sustained plasma levels and increased bioavailability, formulated as nanoparticle or microparticle compositions for controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa is administered orally for Parkinson's disease treatment, then dopamine replacement therapy is achieved, but plasma drug concentration fluctuations occur due to short half-life and rapid degradation
Solution Approach 1:
The patent applies preliminary action by modifying levodopa into prodrug formulations (esters, amides, carbamates) before administration. These modified forms protect levodopa from premature degradation in the periphery, allowing it to reach the brain intact and then be converted to dopamine, thereby stabilizing plasma concentrations and extending half-life.
Solution Approach 2:
The patent changes the chemical parameters of levodopa by introducing fatty acid or fatty alcohol substituents at specific positions (R1-R8 in the patent notation). These structural modifications alter the pharmacokinetic properties, reducing metabolism by AADC and COMT enzymes, and extending plasma half-life while maintaining therapeutic efficacy.
2Productivity
If high dose levodopa is used to treat Parkinson's disease, then bradykinetic symptoms are controlled, but motor fluctuations and dyskinesia occur due to inconsistent dopamine levels
Solution Approach 1:
The patent ensures continuity of useful action by designing levodopa derivatives with sustained release characteristics. The modified levodopa compounds provide continuous dopamine production in the brain over extended periods, eliminating the on-off fluctuations that occur with conventional levodopa dosing, thereby maintaining motor stability while controlling symptoms.
3Reliability
If levodopa is administered multiple times every day, then therapeutic effect is maintained, but patient compliance is reduced and dosing burden increases
Solution Approach 1:
The patent introduces dynamics by creating levodopa prodrugs that release active levodopa gradually over time. This dynamic release mechanism allows for once-daily or less frequent dosing while maintaining consistent therapeutic levels in the brain, significantly improving ease of operation and patient compliance compared to multiple daily doses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The derivatives provide stable dopamine levels in the brain with reduced dosing frequency, improved bioavailability, and decreased side effects, enhancing treatment efficacy and patient compliance.
Implementation Method 1
Levodopa is absorbed in the small bowel and 95% of an administered oral dose is pre-systemically decarboxylated to dopamine by the aromatic L-amino acid decarboxylase (AADC) enzyme in the stomach, lumen of the intestine, kidney, and liver. Levodopa may also be methoxylated by the hepatic catechol-O-methyltransferase (COMT) enzyme system to 3-Omethyldopa (3-OMD), which cannot be converted to central dopamine.
Implementation Method 2
Levodopa, unlike dopamine, can cross the blood brain barrier (BBB) and is converted to dopamine in the central nervous system as well as in peripheral circulation
Implementation Method 3
formulated as nanoparticle or microparticle compositions for controlled release
Data Source
AI summary
A levodopa derivative including a compound or pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein the compound includes substituents which, in aggregate, contain at least 6 carbon atoms which are only bonded to either other carbon atoms or to hydrogen atoms. The levodopa derivative may be formulated as a composition including one or more pharmaceutically acceptable carriers or excipients. The levodopa derivative may be part of a pharmaceutical composition including micro or nano particles in which the levodopa derivative is encapsulated in the pharmaceutically acceptable polymer. The levodopa derivative can be used to treat Parkinson's disease by administering to a mammal an amount sufficient to treat Parkinson's disease.